{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T00:02:47Z","timestamp":1794528167805,"version":"4.9.1"},"publisher-location":"New York, NY","reference-count":16,"publisher":"Springer New York","isbn-type":[{"value":"9781493940097","type":"print"},{"value":"9781493940110","type":"electronic"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/978-1-4939-4011-0_13","type":"book-chapter","created":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T00:40:51Z","timestamp":1472604051000},"page":"149-157","source":"Crossref","is-referenced-by-count":1,"title":["A Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations"],"prefix":"10.1007","author":[{"given":"Zhiqiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenYong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,1]]},"reference":[{"key":"13_CR1","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876\u2013880","journal-title":"Science"},{"key":"13_CR2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117\u2013125","journal-title":"Cancer Cell"},{"key":"13_CR3","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K et al (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99:3472\u20133475","journal-title":"Blood"},{"key":"13_CR4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129\u2013141","journal-title":"Cancer Cell"},{"key":"13_CR5","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood-2005-12-010132","volume":"108","author":"N Bubnoff von","year":"2006","unstructured":"von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J (2006) Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 108:1328\u20131333","journal-title":"Blood"},{"key":"13_CR6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399\u2013401","journal-title":"Science"},{"key":"13_CR7","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"FX Mahon","year":"2000","unstructured":"Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM et al (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96:1070\u20131079","journal-title":"Blood"},{"key":"13_CR8","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2004-06-2445","volume":"105","author":"N Bubnoff von","year":"2005","unstructured":"von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sanger J, Seipel P et al (2005) A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 105:1652\u20131659","journal-title":"Blood"},{"key":"13_CR9","first-page":"7149","volume":"62","author":"P Rosee La","year":"2002","unstructured":"La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ (2002) Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 62:7149\u20137153","journal-title":"Cancer Res"},{"key":"13_CR10","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen HA, Eide CA, O\u2019Hare T, Johnson KJ, Willis SG, Lee FY et al (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108:2332\u20132338","journal-title":"Blood"},{"key":"13_CR11","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/blood-2006-01-015347","volume":"109","author":"A Ray","year":"2007","unstructured":"Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD (2007) Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 109:5011\u20135015","journal-title":"Blood"},{"key":"13_CR12","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","volume":"112","author":"M Azam","year":"2003","unstructured":"Azam M, Latek RR, Daley GQ (2003) Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112:831\u2013843","journal-title":"Cell"},{"key":"13_CR13","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1073\/pnas.0409770102","volume":"102","author":"MR Burgess","year":"2005","unstructured":"Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL (2005) Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A 102:3395\u20133400","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13_CR14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","volume":"108","author":"M Koptyra","year":"2006","unstructured":"Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M et al (2006) BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 108:319\u2013327","journal-title":"Blood"},{"key":"13_CR15","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jnci\/djk150","volume":"99","author":"X Jiang","year":"2007","unstructured":"Jiang X, Saw KM, Eaves A, Eaves C (2007) Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 99:680\u2013693","journal-title":"J Natl Cancer Inst"},{"key":"13_CR16","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1074\/jbc.M109.039206","volume":"285","author":"H Yuan","year":"2010","unstructured":"Yuan H, Wang Z, Gao C, Chen W, Huang Q, Yee JK et al (2010) BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. J Biol Chem 285:5085\u20135096","journal-title":"J Biol Chem"}],"container-title":["Methods in Molecular Biology","Chronic Myeloid Leukemia"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-4011-0_13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:21:34Z","timestamp":1601040094000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-4011-0_13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9781493940097","9781493940110"],"references-count":16,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-4011-0_13","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-4939-4011-0","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}